cyrilzakka/clinical-trials huggingface dataset:
A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care

To describe the current treatment practice during 12 months for previously treated patients diagnosed with haemophilia A or haemophilia B.

The study population consists of patients with a diagnosis of ICD10: haemophilia A D66.9 or haemophilia B D67.9.

Eligibility Criteria:
Inclusion Criteria:

* Male patients with severe or moderate haemophilia A or haemophilia B.
* Treatment with Factor VIII/Factor IX products initiated at least 24 months before inclusion in the study.
* Informed consent is obtained from the patient or patient's legal representative (as applicable according to legal regulation).

Exclusion Criteria:

* Confirmed positive inhibitor test detected in the past 24 months.
Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome

The objective of this study is to conduct a randomized, single-blinded placebo controlled trial comparing two modalities for the treatment of pain and mobility associated with trochanteric bursitis: (1) injection of glucocorticosteroid and local anesthetic, (2) injection of local anesthetic. We hope to determine whether steroid injections provide a statistically significant improvement in pain symptoms and hip mobility in subjects with trochanteric bursitis, as compared to an injection of local anesthetic. Our null hypothesis is that no statistically significant difference exists between the two treatment modalities.

Trochanteric bursitis is an inflammation of the bursal sac overlying the greater trochanter of the femur. The etiology of this disease is unknown, but it is clinically characterized by chronic aching pain over the lateral aspect of the hip, which can be exacerbated by certain movements such as external rotation and abduction (2). In order to objectively determine the level of pain and mobility associated with trochanteric bursitis, some orthopaedic surgeons use scoring systems (a qualitative and quantitative scoring test) to assess patients (4).

In our practice, trochanteric bursitis has been treated by injection of glucocorticosteroids (steroids) combined with local anesthetic at the site of the greater trochanter (1). Additionally, it has been found that increasing steroid dosage provides a greater level of relief (3). Although steroids are usually an effective treatment, no studies to date have compared steroid injections for relief of trochanteric bursitis pain and mobility versus a placebo injection or local anesthetic injection alone.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients with tenderness at the greater trochanter

Exclusion Criteria:

* Subjects \< 17 years of age
* Subjects with previous surgery to the greater trochanter
* Subjects allergic to Lidocaine, Marcaine, or Depomedrol
Intranasal Remimazolam for Premedication in Pediatric Patient

Anesthetic inhalation induction could be one of the most stressful experiences for children during the perioperative period, with almost 50% of them showing anxiety. It is an essential challenge for pediatric anesthesiologists on how to decrease anxiety for children in the operating room (OR) environment and to facilitate a smooth induction of anesthesia. Various factors like parental separation, unfamiliar surroundings, fear of physicians and needle injections can increase their preoperative anxiety. The researchers conducted the current study to investigate whether intranasal remimazolam can reduce anxiety in children before surgery.

children aged 2-5 years old were randomly allocated into three equal groups based on the premedication routes: Group R with intranasal remimazolam, Group D with intranasal dexmedetomidine and Group P with intranasal placebo, respectively.

Eligibility Criteria:
Inclusion Criteria:

1. with American Society of Anesthesiologists (ASA) physical status I or II；
2. aged 2-5 years；
3. children with weight for age within the normal range
4. were scheduled surgery with general anesthesia

Exclusion Criteria:

1. Children who had gastrointestinal,Cardiovascular or endocrine dysfunction;
2. contraindication to preoperative sedation or had a known allergy or hypersensitive reaction to either dexmedetomidine or remimazolam;
3. with any nasal pathology,organ dysfunction;
4. recently respiratory infection, mental disorder;
5. other reasons that researchers hold it is not appropriate to participate in this trial.-
Snacking, Satiety &Weight: A Randomized, Controlled Trial

Proposed is a parallel-design randomized controlled trial to compare the effects of consuming two types of snacks on a daily basis for a 12-week period on health outcomes, diet quality, and self-reported satiety in a group of overweight adults. The types of snacks to be studied are KIND snack bars with almonds and typical American snack foods).

Snacking has been implicated in the obesity epidemic, but judicious snacking can help control appetite and calorie intake and add nutrient-dense foods to the diet. The investigators hypothesize that snacking on nutrient-dense, highly satiating snack foods (i.e. KIND snacks with almonds) as compared to snacking on nutrient-dilute, energy-dense foods (i.e., conventional snack foods) will contribute to satiety, weight loss, and health improvements. The investigators further hypothesize that the benefits of healthful snacking are enhanced when portion is clearly defined and controlled by packaging. Finally, the investigators hypothesize that these effects will be seen even when study participants are given clear guidance about the calorie content of snack items, and how to make room for those calories in their diets.

Hypotheses:

1. Snacking on nutrient-dense, highly satiating snack foods (i.e. KIND snacks with almonds) as compared to snacking on nutrient-dilute, energy-dense foods (i.e., conventional snack foods) will contribute to satiety, weight loss, and health improvements.
2. The benefits of healthful snacking are enhanced when portion size is clearly defined and controlled by packaging.
3. These effects will be seen even when study participants are given clear guidance about the calorie content of snack items, and how to make room for those calories in their diets.

Eligibility Criteria:
Inclusion Criteria:

* Man or woman age 25-75 years;
* Non-smoker;
* Sedentary;
* Overweight (BMI ≥25kg/m²) with waist circumference \>40 inches (102 cm) for men and \>35 inches (88 cm) for women;
* Interested in losing weight, but not actively involved with a diet or weight loss program.
* Snack regularly with pre-packaged snacks typically available in grocery stores or vending machines.
* Willing to consume snacks on a daily basis.

Exclusion Criteria:

* Failure to meet inclusion criteria;
* Anticipated inability to complete study protocol for any reason;
* Current eating disorder;
* Diabetes;
* Sleep apnea;
* Actively involved with a diet or weight loss program;
* Other restricted diets due to allergy/intolerance (i.e. nut, gluten) or by choice (i.e., vegetarian, vegan);
* Regular exercise as defined by participating in moderate-intensity for at least 150 minutes/week.
Study Evaluating Etanercept in Patients With Ankylosing Spondylitis

This study will assess the efficacy of etanercept for the treatment of Ankylosing Spondylitis (AS).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of AS, as defined by Modified New York Criteria for Ankylosing Spondylitis, aged between 18 and 70 years of age.
* BASDAI greater than or equal to 40 (all scores on a scale of 0 to 100).
* Negative result of serum human chorionic gonadotropin (HCG) pregnancy test taken at screening in all women except those surgically sterile or at least 1 year postmenopausal.

Exclusion Criteria:

* Complete ankylosis (fusion) of spine.
* Previous receipt of etanercept, antibody to TNFα, or other TNFα inhibitors.
* Use of disease modifying antirheumatic drugs (DMARDs) other than hydroxychloroquine, sulphasalazine, and methotrexate within 4 weeks of baseline. Patients treated with hydroxychloroquine, sulphasalazine, and methotrexate may continue these drugs during this study but doses must be held stable for 4 weeks before baseline examination and for the duration of the study.
A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects

This study evaluates the usefulness of a PET radioligand to estimate the binding on the mGlu4 receptor in the brain. mGlu4 has been proposed as a therapeutic target in Parkinson's disease.


Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects age 20-50 inclusive
* Body mass index (BMI) between 19 and 30 kg/m2
* Normal sMRI scan, performed within 3 months, as judged by the investigator
* The subject is, in the opinion of the investigator, generally healthy based on assessment of medical history, physical examination, vital signs, ECG, and the results of the hematology, clinical chemistry, urinalysis, serology, and other laboratory tests
* Women of childbearing potential and men whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the trial and for 3 months thereafter
* A propensity to tolerate confined spaces for prolonged periods
* Suitability for radial and/or brachial artery blood sampling and cannulation

Exclusion Criteria:

* History of clinically significant cardio-or cerebrovascular, pulmonary, renal, hepatic, neurological, mental or gastrointestinal disorder or any other major disorder that may interfere with the objectives of the study, as judged by the investigator
* The subject has 1 or more clinical laboratory test values outside the reference range, which in the opinion of the investigator are clinically significant
* Screening supine blood pressure \>=140 mm Hg (systolic) or \>=90 mm Hg (diastolic), following at least 5 minutes of supine rest. If blood pressure (BP) is \>=140 mm Hg (systolic) or \>=90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility
* The subject has a resting pulse \<=50 or \>=100 bpm at the Screening Visit
* The subject has a QTc interval \>430 ms (Bazett's or Fridericia's correction) at the Screening Visit or at he Baseline Visit, as calculated by the ECG equipment and evaluated by the investigator. The ECG may be repeated if any of the values are out-of-range or abnormal
* The subject is pregnant or breastfeeding
* Habitual use of nicotine products and addictive substances
* Any finding of significance on MRI scans as judged by the investigator.
* Any previous PET measurements for scientific purposes
* Use of CNS active drugs and/or NSAIDs 1 month prior to the first PET examination
* The subject is exposed to significant level of ionizing radiation at work
* The subject has undergone any clinical procedures involving significant exposure to radiation (excluding dental X-ray and common X-rays of the chest or extremities)
* The subject has received radio labeled material less than 12
Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging Algorithm

Ovarian cancer is relatively rare but fatal with an annual incidence rate of 11.8 per 100 000 and a high mortality-to-incidence ratio of \>0.6. The modest diagnostic accuracy of TVU has risen some concerns about the over-treatment.Now, with the development of artificial intelligence (AI), we may have a better chance to interpret TVU imagines with high efficiency, reproducibility and accuracy.


Eligibility Criteria:
Inclusion Criteria:

* Women scheduled for Transvaginal Ultrasound examination for adnexal lesions;
* Women aged over 18 years old;
* Women willing to participant in this study evidenced by signing the informed consent.

Exclusion Criteria:

* Women without adnexa for any reasons at the time of Transvaginal Ultrasound examination, including but not limited to receiving surgical removal for adnexa;
* Women with a pathologic diagnosis of ovarian cancer before the Transvaginal Ultrasound examination;
* Women with mental abnormal;
* Women did not cooperate or participate in other clinical trials;
* Pregnant or lactating women.
Impact of Kinesio Taping on Kyphosis and Quality of Life in Adolescents

Kyphosis, a posture disorder, is excessive curvature of the thoracic area in the spine. In a healthy person, there is a normal kyphosis angulation in the thoracic and sacral areas in the sagittal plane. Since the sacral area is more stable, pathological conditions generally occur in the thoracic area.

Kyphosis causes a bowing of the back, which leads to a hunchback or slouching posture. Normal values for the thoracic kyphosis are between 20˚ and 40˚ of angulations. When the curve of the thoracic spine exceeds this, it is described as either a postural kyphosis or Scheuermann\&#39;s kyphosis.

The study question is: Does kinesio taping have an effect on kyphosis and quality of life in adolescents?

The purpose of the study is to determine the effects of kinesio taping on:

* Kyphotic curve.
* Forward head posture.
* Quality of life in adolescents. Postural kyphosis is the most common type that causes slouching in thoracic curve can occur in young age, it can be called \&#39;slouching\&#39; and is reversible by correcting muscular imbalances.

Adolescent\&#39;s kyphosis curve appear by bad habitual postures due to a carry-over effect from temporary changes in posture during computer use and smart phones.

Forward head posture (FHP) is characterized that cervical spine is held in protracted position for prolonged duration, it can lead to alterations in head posture ultimately leading to poor posture which is thought to be a deviation from neutral or normal posture.

Failure of the head to align with the vertical axis of the body can lead to further malalignments in the body, namely, rounded shoulders and increased thoracic kyphosis, to compensate for the altered location of the LOG, leading to further impairments . A combination of all these postural deviations is often known as "slouched posture" or "slumped posture." The Kinesio taping method was applied to correct the alignment of weak muscles as well as facilitating joint motion as a result of the tape\&#39;s recoiling qualities. It was designed to be the approximate thickness and elasticity of skin and be worn three to five days at a time.

Kinesio taping is a therapeutic tool used with increasing frequency within musculoskeletal rehabilitation and to maintain preferred body alignment. It is a complementary treatment and is designed to facilitate the body's natural healing, Process while allowing support and stability to 5 muscles and joints without restricting the body's range of motion.

Due to the lack of research area of kinesio taping on kyphosis in adolescents, So, the purpose of the study is to know impact of the Kinesio taping on kyphosis and quality of life in adolescents.

Eligibility Criteria:
Inclusion Criteria:

* Their age will be ranged from 15 to 18 years.
* They will have forward head posture.
* They will have postural kyphosis with Cobb\&#39;s angle more than 45 degree.
* Their body mass index of female adolescents will be ranged between (19.5 - 20.7)

Exclusion Criteria:

* Visual or hearing defects.
* Congenital anomalies in spine region.
* Fractures of upper limb.
Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial

The aim of this study is to evaluate the efficacy and safety of AZT and MTX in patients with Chronic Actinic Dermatitis (CAD). These drugs have been used successfully as steroid-sparing alternatives in a variety of related dermatoses and this trial may help in paving the path towards the ubiquitous use of these cost-effective and relatively safer drugs in CAD patients of our population. The researchers will try to answer the following questions:

1. Is methotrexate safe and efficacious in treating CAD?
2. Is there a difference in efficacy of methotrexate and azathioprine in the treatment of this disease?

After the enrollment of patients and taking consent, participants will be divided in two treatment groups via lottery method. Group A will be administered oral methotrexate 10mg/week after a test dose while group B will be administered tablet azathioprine at a dose of 0.3mg/kg daily after. Both group of patients will be advised regarding strict sun protection measures (sunblock, hats, sunglasses etc.). The baseline investigations for both groups will include complete blood picture (CBC), liver function tests (LFTs), renal function tests (RFTs), electrocardiogram, chest X-ray and urine analysis while thiopurine methyltransferase (TPMT) levels will be assessed specifically for group B patients. The patients will be followed up at week 4, 12 and 24. CBC, RFTs and LFTs will be done at each follow-up and EASI score will be calculated,


Eligibility Criteria:
Inclusion Criteria:

* All newly diagnosed as well as patients with an established diagnosis of CAD presenting to the outpatient department or the emergency department of PEMH or CMH will be included in the study.

Exclusion Criteria:

* Patients with coexisting conditions requiring immunosuppressants will be excluded from the study. Patients with dementia or any other neuropsychiatric disorder will also be excluded.
Comparison of the Effect of Two Treatments on the Nutritional and Micronutrient Status of Malnourished Children

The purpose of this study is to measure the impact of a fortified food on the nutritional and micronutrient status of malnourished children, compared with milk. The changes to be evaluated include the indicators weight for height, height for age, weight for age, mid-arm circumferance for age; and levels of hemoglobin, serum zinc, serum ferritin, serum folic acid, erythrocyte folic acid, serum vitamin B12, and urinary iodine.

Chronic malnutrition evidenced by short height for age is a common nutritional problem in underdeveloped countries which is generally accompanied by iron deficiency anemia and zinc deficiency. It has many consequences on the adult including limited capacity to work and higher risk of obesity and chronic disease. The present study will offer a fortified food, culturally accepted and locally produced. The effectiveness of this fortified food compared to lactose-free milk, in a controlled dose and with no risk to the health of the study participants, will be determined. Both will be distributed for free to be consumed as an atole or in liquid form, respectively, at a community level in an environment controlled as much as possible. This will allow to determine adherence, acceptability, consumption and distribution within the family.

Eligibility Criteria:
Inclusion Criteria:

* Some degree of malnutrition according to weight for height or height for age
* Reside in one of the six communities chosen for the study

Exclusion Criteria:

* Leukemia
* Diabetes
* Handicap
* Down syndrome
* Renal failure
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery

The study is enrolling adults who are scheduled for either inpatient or outpatient elective surgical procedures at The University of Chicago.

At pre-operative visits, patients will be consented and a blood sample will be obtained for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.

Genotyping results will be delivered to participating providers as patient-specific drug-gene clinical decision support summaries using a secured Web portal, the Genomic Prescribing System (GPS).

Participating anesthesiologists and critical care and pain management physicians and associated providers from the Department of Anesthesia and Critical Care at the University of Chicago will be invited to receive results for their participating patients.

There will be an initial 6- month "run-in" period of the study comprised of approximately 100 enrolled adults in which all patients will have pharmacogenomic results made available to providers. The run-in period will allow for process refinement and GPS delivery to be examined and optimized prior to the randomized phase

After the initial run-in period, patients will be randomized to one of two arms - in the pharmacogenomic arm, providers will have access to GPS and pharmacogenomic information, whereas in the control arm, providers will not have access to GPS and patient-specific pharmacogenomic information (current standard of care).


Eligibility Criteria:
Inclusion Criteria:

* Adult patients who have planned elective surgical procedures at the University of Chicago
* Must be aged 18 years or older

Exclusion Criteria:

* Patients who have undergone, or are being actively considered for, liver or kidney transplantation
* Patients with known active or prior leukemia.
* Inability to understand and give informed consent to participate.
Cutting-through at the Greater Tuberosity

The investigators evaluated the correlation between cutting-through at the greater tuberosity (GT) just medial to the lateral knotless anchor in arthroscopic suture-bridge rotator cuff repair and the bone mineral density (BMD) of the lumbar spine, hip and GT of the proximal humerus and to evaluate factors and clinical outcomes related to cutting-through at the GT.

Seventy-eight patients who underwent arthroscopic suture-bridge rotator cuff repair and who had undergone dual energy X-ray absorptiometry (DEXA) scans before surgery were included. Patients were divided into two groups: patients who had cutting-through (46, group I) and patients who did not (32, group II). Clinical and radiological data including demographics, BMDs, fatty infiltration of rotator cuff muscles, tear size, tear involvement, VAS pain score, and ASES score were analyzed.

Eligibility Criteria:
Inclusion Criteria:

1. Primary arthroscopic repair for a symptomatic full-thickness rotator cuff tear identified by preoperative MRI
2. Dual energy X-ray absorptiometry (DEXA) to evaluate the BMD of the lumbar spine and hip, as a standardized measurement, and the GT of the affected proximal humerus
3. Follow up for a minimum of 2 years after the primary surgery.

Exclusion Criteria:

1. Primary arthroscopic repair due to partial-thickness rotator cuff tear or an isolated subscapularis tear
2. Primary suture-bridge repair with 3 or more lateral-knotless anchors
3. Previous history of fractures or surgeries on the affected shoulder
4. Shoulder instability
5. Glenohumeral osteoarthritis
6. Neurologic or systemic disease diseases influencing the shoulder joint 7 History of infection of the shoulder joint
Unmet Needs of Axial Spondyloarthrits in Egyptian Patients

During the past decade, the well-known disease called Ankylosing Spondylitis has come to be considered as a subset of the broader entity referred as axial spondyloarthritis (axSpA), which also includes non-radiographic axSpA. The need of this new classification was aimed to improve the sensitivity for an early diagnosis, to reduce diagnostic delay, and to allow an early treatment. Although there is improvement in the recognition, the management of patients, and the treatment strategies of axSpA, unmet needs persist , there is still a substantial gap of 5-8 years between the onset of symptoms and the diagnosis of axSpA.

. This study is intended to enhance awareness and understanding of Axial Spondyloarthritis and to identify and discuss the current unmet needs in axSpA .

Multiple defects are still unfullfilled for axial SpA patients those defects include delayed diagnosis specially for female, failure to acheive treatment target, pain, impaired quality of life and associated comorbidities.

Up to the best of our knowledge this is the first study to highlight unmet needs for axial Spondyloarthritis patients in Egypt in general and in upper Egypt in particular .


Eligibility Criteria:
Inclusion Criteria

* Patients fulfill the Assessment in Spondyloarthrits International Society (ASAS) classification criteria for Axial Spondyloarthritis .
* Age above 16 years old.
* Patient cooperative and can answer questions .

Exclusion Criteria:

* Other rheumatologic or collagen diseases .
* Age below 16 years and above 60 years.
* Uncooperative patients .